Chemotherapy induces the cancer-associated fibroblast phenotype, activating paracrine Hedgehog-GLI signalling in breast cancer cells

Oncotarget

Volumn 6, Issue 13, 2015, Pages 10728-10745

  Peiris Pagès, Maria ^a,b   Sotgia, Federica ^a,b   Lisanti, Michael ^a,b  

^a UNIVERSITY OF MANCHESTER   (United Kingdom)

^b UNIVERSITY OF MANCHESTER   (United Kingdom)

Author keywords

Chemotherapy; Metabolism; Second primary tumours; Tumour microenvironment

Indexed keywords

ALPHA SMOOTH MUSCLE ACTIN; ANTINEOPLASTIC AGENT; HYPOXIA INDUCIBLE FACTOR 1; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; INTERLEUKIN 6; SMAD PROTEIN; SONIC HEDGEHOG PROTEIN; STAT3 PROTEIN; STRESS ACTIVATED PROTEIN KINASE; TRANSCRIPTION FACTOR; TRANSCRIPTION FACTOR AP 1; TRANSCRIPTION FACTOR GLI; TRANSFORMING GROWTH FACTOR BETA; UNCLASSIFIED DRUG; ANTIOXIDANT; AUTACOID; CYTOKINE; GLI1 PROTEIN, HUMAN; TRANSCRIPTION FACTOR GLI1;

ARTICLE; AUTOPHAGY; CANCER ASSOCIATED FIBROBLAST; CANCER CELL; CATABOLISM; CELL AGING; CELL INTERACTION; CELL MIGRATION; CELL TRANSFORMATION; COCULTURE; CONTROLLED STUDY; CYTOKINE RELEASE; ENZYME ACTIVATION; FIBROBLAST; HUMAN; HUMAN CELL; IMMUNE RESPONSE; IN VITRO STUDY; OXIDATIVE STRESS; PARACRINE SIGNALING; PHENOTYPE; PROTEIN EXPRESSION; TUMOR MICROENVIRONMENT; BREAST NEOPLASMS; CANCER STEM CELL; DOSE RESPONSE; DRUG EFFECTS; FEMALE; GENETIC TRANSFECTION; GENETICS; GLYCOLYSIS; MCF-7 CELL LINE; METABOLISM; PATHOLOGY; SIGNAL TRANSDUCTION; TIME FACTOR;

ANTINEOPLASTIC AGENTS; ANTIOXIDANTS; AUTOPHAGY; BREAST NEOPLASMS; CELL AGING; COCULTURE TECHNIQUES; CYTOKINES; DOSE-RESPONSE RELATIONSHIP, DRUG; FEMALE; FIBROBLASTS; GLYCOLYSIS; HEDGEHOG PROTEINS; HUMANS; INFLAMMATION MEDIATORS; MCF-7 CELLS; NEOPLASTIC STEM CELLS; OXIDATIVE STRESS; PARACRINE COMMUNICATION; PHENOTYPE; SIGNAL TRANSDUCTION; TIME FACTORS; TRANSCRIPTION FACTORS; TRANSFECTION; TUMOR MICROENVIRONMENT; ZINC FINGER PROTEIN GLI1;

EID: 84929613454     PISSN: None     EISSN: 19492553     Source Type: Journal    
DOI: 10.18632/oncotarget.3828     Document Type: Article

References (59)

1. Hanahan D and Coussens LM. Accessories to the crime:functions of cells recruited to the tumor microenvironment. Cancer Cell. 2012; 21:309-322.
2. Ronnov-Jessen L and Petersen OW. Induction of alphasmooth muscle actin by transforming growth factor-beta 1 in quiescent human breast gland fibroblasts. Implications for myofibroblast generation in breast neoplasia. Lab Invest. 1993; 68:696-707.
3. Bartling B, Hofmann HS, Silber RE and Simm A. Differential impact of fibroblasts on the efficient cell death of lung cancer cells induced by paclitaxel and cisplatin. Cancer Biol Ther. 2008; 7:1250-1261.
4. Nieman KM, Kenny HA, Penicka CV, Ladanyi A, Buell-Gutbrod R, Zillhardt MR, Romero IL, Carey MS, Mills GB, Hotamisligil GS, Yamada SD, Peter ME, Gwin K and Lengyel E. Adipocytes promote ovarian cancer metastasis and provide energy for rapid tumor growth. Nat Med. 2011; 17:1498-1503.
5. Zhang W, Trachootham D, Liu J, Chen G, Pelicano H, Garcia-Prieto C, Lu W, Burger JA, Croce CM, Plunkett W, Keating MJ and Huang P. Stromal control of cystine metabolism promotes cancer cell survival in chronic lymphocytic leukaemia. Nat Cell Biol. 2012; 14:276-286.
6. Martinez-Outschoorn U, Sotgia F and Lisanti MP. Tumor microenvironment and metabolic synergy in breast cancers:critical importance of mitochondrial fuels and function. Seminars in oncology. 2014; 41:195-216.
7. Laberge RM, Awad P, Campisi J and Desprez PY. Epithelial-mesenchymal transition induced by senescent fibroblasts. Cancer Microenviron. 2012; 5:39-44.
8. Martinez-Outschoorn UE, Lin Z, Ko YH, Goldberg AF, Flomenberg N, Wang C, Pavlides S, Pestell RG, Howell A, Sotgia F and Lisanti MP. Understanding the metabolic basis of drug resistance: therapeutic induction of the Warburg effect kills cancer cells. Cell Cycle. 2011; 10:2521-2528.
9. Porter DC, Farmaki E, Altilia S, Schools GP, West DK, Chen M, Chang BD, Puzyrev AT, Lim CU, Rokow-Kittell R, Friedhoff LT, Papavassiliou AG, Kalurupalle S, Hurteau G, Shi J, Baran PS, et al. Cyclin-dependent kinase 8 mediates chemotherapy-induced tumor-promoting paracrine activities. Proc Natl Acad Sci U S A. 2012; 109:13799-13804.
10. Allan JM and Travis LB. Mechanisms of therapy-related carcinogenesis. Nat Rev Cancer. 2005; 5(12):943-955.
11. Boice JD, Jr., Blettner M, Kleinerman RA, Stovall M, Moloney WC, Engholm G, Austin DF, Bosch A, Cookfair DL, Krementz ET and et al. Radiation dose and leukemia risk in patients treated for cancer of the cervix. J Natl Cancer Inst. 1987; 79:1295-1311.
12. Bonuccelli G, Tsirigos A, Whitaker-Menezes D, Pavlides S, Pestell RG, Chiavarina B, Frank PG, Flomenberg N, Howell A, Martinez-Outschoorn UE, Sotgia F and Lisanti MP. Ketones and lactate "fuel" tumor growth and metastasis: Evidence that epithelial cancer cells use oxidative mitochondrial metabolism. Cell Cycle. 2010; 9:3506-3514.
13. Kumari KK and Setty OH. Protective effect of Phyllanthus fraternus against mitochondrial dysfunction induced by co-administration of cisplatin and cyclophosphamide. J Bioenerg Biomembr. 2012; 44:179-188.
14. Velez JM, Miriyala S, Nithipongvanitch R, Noel T, Plabplueng CD, Oberley T, Jungsuwadee P, Van Remmen H, Vore M and St Clair DK. p53 Regulates oxidative stress-mediated retrograde signaling: a novel mechanism for chemotherapy-induced cardiac injury. PLoS One. 2011; 6:e18005.
15. Toullec A, Gerald D, Despouy G, Bourachot B, Cardon M, Lefort S, Richardson M, Rigaill G, Parrini MC, Lucchesi C, Bellanger D, Stern MH, Dubois T, Sastre-Garau X, Delattre O, Vincent-Salomon A, et al. Oxidative stress promotes myofibroblast differentiation and tumour spreading. EMBO Mol Med. 2010; 2:211-230.
16. Demaria M, Camporeale A and Poli V. STAT3 and metabolism: how many ways to use a single molecule? Int J Cancer. 2014; 135:1997-2003.
17. Campisi J and d'Adda di Fagagna F. Cellular senescence:when bad things happen to good cells. Nature reviews Molecular cell biology. 2007; 8:729-740.
18. Goehe RW, Di X, Sharma K, Bristol ML, Henderson SC, Valerie K, Rodier F, Davalos AR and Gewirtz DA. The autophagy-senescence connection in chemotherapy: must tumor cells (self) eat before they sleep? J Pharmacol Exp Ther. 2012; 343:763-778.
19. Chang BD, Swift ME, Shen M, Fang J, Broude EV and Roninson IB. Molecular determinants of terminal growth arrest induced in tumor cells by a chemotherapeutic agent. Proc Natl Acad Sci U S A. 2002; 99:389-394.
20. Rodier F, Coppe JP, Patil CK, Hoeijmakers WA, Munoz DP, Raza SR, Freund A, Campeau E, Davalos AR and Campisi J. Persistent DNA damage signalling triggers senescence-associated inflammatory cytokine secretion. Nat Cell Biol. 2009; 11:973-979.
21. Martinez-Outschoorn UE, Whitaker-Menezes D, Lin Z, Flomenberg N, Howell A, Pestell RG, Lisanti MP and Sotgia F. Cytokine production and inflammation drive autophagy in the tumor microenvironment: role of stromal caveolin-1 as a key regulator. Cell Cycle. 2011; 10:1784-1793.
22. Paunescu V, Bojin FM, Tatu CA, Gavriliuc OI, Rosca A, Gruia AT, Tanasie G, Bunu C, Crisnic D, Gherghiceanu M, Tatu FR, Tatu CS and Vermesan S. Tumour-associated fibroblasts and mesenchymal stem cells: more similarities than differences. J Cell Mol Med. 2011; 15:635-646.
23. Pavlides S, Whitaker-Menezes D, Castello-Cros R, Flomenberg N, Witkiewicz AK, Frank PG, Casimiro MC, Wang C, Fortina P, Addya S, Pestell RG, Martinez-Outschoorn UE, Sotgia F and Lisanti MP. The reverse Warburg effect: aerobic glycolysis in cancer associated fibroblasts and the tumor stroma. Cell Cycle. 2009; 8:3984-4001.
24. Tavares-Valente D, Baltazar F, Moreira R and Queiros O. Cancer cell bioenergetics and pH regulation influence breast cancer cell resistance to paclitaxel and doxorubicin. J Bioenerg Biomembr. 2013; 45:467-475.
25. Martinez-Outschoorn UE, Prisco M, Ertel A, Tsirigos A, Lin Z, Pavlides S, Wang C, Flomenberg N, Knudsen ES, Howell A, Pestell RG, Sotgia F and Lisanti MP. Ketones and lactate increase cancer cell "stemness," driving recurrence, metastasis and poor clinical outcome in breast cancer: achieving personalized medicine via Metabolo-Genomics. Cell Cycle. 2011; 10:1271-1286.
26. Pavlides S, Tsirigos A, Migneco G, Whitaker-Menezes D, Chiavarina B, Flomenberg N, Frank PG, Casimiro MC, Wang C, Pestell RG, Martinez-Outschoorn UE, Howell A, Sotgia F and Lisanti MP. The autophagic tumor stroma model of cancer: Role of oxidative stress and ketone production in fueling tumor cell metabolism. Cell Cycle. 2010; 9:3485-3505.
27. Chiavarina B, Martinez-Outschoorn UE, Whitaker-Menezes D, Howell A, Tanowitz HB, Pestell RG, Sotgia F and Lisanti MP. Metabolic reprogramming and twocompartment tumor metabolism: opposing role(s) of HIF1alpha and HIF2alpha in tumor-associated fibroblasts and human breast cancer cells. Cell Cycle. 2012; 11:3280-3289.
28. Chiavarina B, Whitaker-Menezes D, Migneco G, Martinez-Outschoorn UE, Pavlides S, Howell A, Tanowitz HB, Casimiro MC, Wang C, Pestell RG, Grieshaber P, Caro J, Sotgia F and Lisanti MP. HIF1-alpha functions as a tumor promoter in cancer associated fibroblasts, and as a tumor suppressor in breast cancer cells: Autophagy drives compartment-specific oncogenesis. Cell Cycle. 2010; 9:3534-3551.
29. Guido C, Whitaker-Menezes D, Capparelli C, Balliet R, Lin Z, Pestell RG, Howell A, Aquila S, Ando S, Martinez-Outschoorn U, Sotgia F and Lisanti MP. Metabolic reprogramming of cancer-associated fibroblasts by TGFbeta drives tumor growth: connecting TGF-beta signaling with "Warburg-like" cancer metabolism and L-lactate production. Cell Cycle. 2012; 11:3019-3035.
30. Martinez-Outschoorn UE, Lisanti MP and Sotgia F. Catabolic cancer-associated fibroblasts transfer energy and biomass to anabolic cancer cells, fueling tumor growth. Seminars in cancer biology. 2014; 25:47-60.
31. Blobe GC, Schiemann WP and Lodish HF. Role of transforming growth factor beta in human disease. N Engl J Med. 2000; 342:1350-1358.
32. Ng IH, Yeap YY, Ong LS, Jans DA and Bogoyevitch MA. Oxidative stress impairs multiple regulatory events to drive persistent cytokine-stimulated STAT3 phosphorylation. Biochimica et biophysica acta. 2014; 1843:483-494.
33. Boyd NF, Rommens JM, Vogt K, Lee V, Hopper JL, Yaffe MJ and Paterson AD. Mammographic breast density as an intermediate phenotype for breast cancer. The Lancet Oncology. 2005; 6:798-808.
34. Capparelli C, Chiavarina B, Whitaker-Menezes D, Pestell TG, Pestell RG, Hulit J, Ando S, Howell A, Martinez-Outschoorn UE, Sotgia F and Lisanti MP. CDK inhibitors (p16/p19/p21) induce senescence and autophagy in cancerassociated fibroblasts, "fueling" tumor growth via paracrine interactions, without an increase in neo-angiogenesis. Cell Cycle. 2012; 11:3599-3610.
35. Capparelli C, Guido C, Whitaker-Menezes D, Bonuccelli G, Balliet R, Pestell TG, Goldberg AF, Pestell RG, Howell A, Sneddon S, Birbe R, Tsirigos A, Martinez-Outschoorn U, Sotgia F and Lisanti MP. Autophagy and senescence in cancer-associated fibroblasts metabolically supports tumor growth and metastasis via glycolysis and ketone production. Cell Cycle. 2012; 11:2285-2302.
36. Martinez-Outschoorn UE, Lin Z, Whitaker-Menezes D, Howell A, Lisanti MP and Sotgia F. Ketone bodies and twocompartment tumor metabolism: stromal ketone production fuels mitochondrial biogenesis in epithelial cancer cells. Cell Cycle. 2012; 11:3956-3963.
37. Yeo SG, Kim DY, Kim KH, Ku JL, Kim JS, Cho MJ, Kim ES and Yoo BC. Hydroxymethylglutaryl-coenzyme a synthase 2 expression is associated with chemoradiotherapy responses in colorectal cancer. Diseases of the colon and rectum. 2012; 55:686-694.
38. Andre T, Meuleman N, Stamatopoulos B, De Bruyn C, Pieters K, Bron D and Lagneaux L. Evidences of early senescence in multiple myeloma bone marrow mesenchymal stromal cells. PLoS One. 2013; 8:e59756.
39. Mulligan HD, Beck SA and Tisdale MJ. Lipid metabolism in cancer cachexia. Br J Cancer. 1992; 66:57-61.
40. Kamp DW, Shacter E and Weitzman SA. Chronic inflammation and cancer: the role of the mitochondria. Oncology. 2011; 25:400-410, 413.
41. Shacter E and Weitzman SA. Chronic inflammation and cancer. Oncology. 2002; 16(2):217-226, 229; discussion 230-212.
42. Mantovani A, Allavena P, Sica A and Balkwill F. Cancerrelated inflammation. Nature. 2008; 454:436-444.
43. Oshima H and Oshima M. The inflammatory network in the gastrointestinal tumor microenvironment: lessons from mouse models. Journal of gastroenterology. 2012; 47:97-106.
44. Al-Dasooqi N, Gibson RJ, Bowen JM and Keefe DM. Matrix metalloproteinases: key regulators in the pathogenesis of chemotherapy-induced mucositis? Cancer chemotherapy and pharmacology. 2009; 64:1-9.
45. Torres MA, Pace TW, Liu T, Felger JC, Mister D, Doho GH, Kohn JN, Barsevick AM, Long Q and Miller AH. Predictors of depression in breast cancer patients treated with radiation: role of prior chemotherapy and nuclear factor kappa B. Cancer. 2013; 119:1951-1959.
46. Briscoe J and Therond PP. The mechanisms of Hedgehog signalling and its roles in development and disease. Nature reviews Molecular cell biology. 2013; 14:416-429.
47. Spitzner M, Ebner R, Wolff HA, Ghadimi BM, Wienands J and Grade M. STAT3: A Novel Molecular Mediator of Resistance to Chemoradiotherapy. Cancers. 2014; 6:1986-2011.
48. Kahn M. Can we safely target the WNT pathway? Nature reviews Drug discovery. 2014; 13:513-532.
49. Teglund S and Toftgard R. Hedgehog beyond medulloblastoma and basal cell carcinoma. Biochimica et biophysica acta. 2010; 1805:181-208.
50. Javelaud D, Pierrat MJ and Mauviel A. Crosstalk between TGF-beta and hedgehog signaling in cancer. FEBS letters. 2012; 586:2016-2025.
51. Harris LG, Samant RS and Shevde LA. Hedgehog signaling: networking to nurture a promalignant tumor microenvironment. Molecular cancer research : MCR. 2011; 9:1165-1174.
52. Zhang Q, Raje V, Yakovlev VA, Yacoub A, Szczepanek K, Meier J, Derecka M, Chen Q, Hu Y, Sisler J, Hamed H, Lesnefsky EJ, Valerie K, Dent P and Larner AC. Mitochondrial localized Stat3 promotes breast cancer growth via phosphorylation of serine 727. J Biol Chem. 2013; 288:31280-31288.
53. Sherwood V, Chaurasiya SK, Ekstrom EJ, Guilmain W, Liu Q, Koeck T, Brown K, Hansson K, Agnarsdottir M, Bergqvist M, Jirstrom K, Ponten F, James P and Andersson T. WNT5A-mediated beta-catenin-independent signalling is a novel regulator of cancer cell metabolism. Carcinogenesis. 2014; 35:784-794.
54. Zhang DD. The Nrf2-Keap1-ARE signaling pathway: The regulation and dual function of Nrf2 in cancer. Antioxid Redox Signal. 2010; 13:1623-1626.
55. No JH, Kim YB and Song YS. Targeting nrf2 signaling to combat chemoresistance. Journal of cancer prevention. 2014; 19:111-117.
56. DeNardo DG, Brennan DJ, Rexhepaj E, Ruffell B, Shiao SL, Madden SF, Gallagher WM, Wadhwani N, Keil SD, Junaid SA, Rugo HS, Hwang ES, Jirstrom K, West BL and Coussens LM. Leukocyte complexity predicts breast cancer survival and functionally regulates response to chemotherapy. Cancer discovery. 2011; 1:54-67.
57. Nakasone ES, Askautrud HA, Kees T, Park JH, Plaks V, Ewald AJ, Fein M, Rasch MG, Tan YX, Qiu J, Park J, Sinha P, Bissell MJ, Frengen E, Werb Z and Egeblad M. Imaging tumor-stroma interactions during chemotherapy reveals contributions of the microenvironment to resistance. Cancer Cell. 2012; 21:488-503.
58. Tye H, Kennedy CL, Najdovska M, McLeod L, McCormack W, Hughes N, Dev A, Sievert W, Ooi CH, Ishikawa TO, Oshima H, Bhathal PS, Parker AE, Oshima M, Tan P and Jenkins BJ. STAT3-driven upregulation of TLR2 promotes gastric tumorigenesis independent of tumor inflammation. Cancer Cell. 2012; 22:466-478.
59. Tymoszuk P, Charoentong P, Hackl H, Spilka R, Muller-Holzner E, Trajanoski Z, Obrist P, Revillion F, Peyrat JP, Fiegl H and Doppler W. High STAT1 mRNA levels but not its tyrosine phosphorylation are associated with macrophage infiltration and bad prognosis in breast cancer. BMC cancer. 2014; 14:257.